Haloxon

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Haloxon
DrugBank Accession Number
DB11419
Background

Not Available

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 415.58
Monoisotopic: 413.9593583
Chemical Formula
C14H14Cl3O6P
Synonyms
  • Haloxon
  • Haloxona
  • Haloxone
  • Haloxonum

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Haloxon.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Haloxon.
DexmethylphenidateThe serum concentration of the active metabolites of Haloxon can be increased when Haloxon is used in combination with Dexmethylphenidate.
DiazoxideThe serum concentration of Haloxon can be increased when it is combined with Diazoxide.
DoxycyclineThe therapeutic efficacy of Haloxon can be increased when used in combination with Doxycycline.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a 1-benzopyran moiety with a ketone group at the C2 carbon atom (1-benzopyran-2-one).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Not Available
Direct Parent
Coumarins and derivatives
Alternative Parents
1-benzopyrans / Pyranones and derivatives / Dialkyl phosphates / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Organooxygen compounds / Organochlorides
show 3 more
Substituents
1-benzopyran / Alkyl chloride / Alkyl halide / Alkyl phosphate / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Benzenoid / Benzopyran / Coumarin
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
T8KXA37068
CAS number
321-55-1
InChI Key
KULDXINYXFTXMO-UHFFFAOYSA-N
InChI
InChI=1S/C14H14Cl3O6P/c1-9-11-3-2-10(8-12(11)22-14(18)13(9)17)23-24(19,20-6-4-15)21-7-5-16/h2-3,8H,4-7H2,1H3
IUPAC Name
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl bis(2-chloroethyl) phosphate
SMILES
CC1=C(Cl)C(=O)OC2=C1C=CC(OP(=O)(OCCCl)OCCCl)=C2

References

General References
  1. Humphreys DJ, Stodulski JB, Fysh RR, Howie NM: Haloxon poisoning in geese. Vet Rec. 1980 Dec 6;107(23):541. [Article]
  2. Cook TF: Toxicity of haloxon in sheep. N Z Vet J. 1966 May-Jun;14(5-6):71-2. [Article]
  3. Benz GW: Anthelmintic activity of haloxon in calves. Am J Vet Res. 1972 Jun;33(6):1273-6. [Article]
  4. Cook TF: The anthelmintic efficiency of haloxon in horses. N Z Vet J. 1973 May;21(5):82-4. [Article]
  5. BAKER NF, DOUGLAS JR: ANTHELMINTIC ACTIVITY OF HALOXON IN LAMBS. Am J Vet Res. 1965 May;26:651-3. [Article]
  6. Beech JA: Field trials with haloxon against Capillaria in laying fowls. Vet Rec. 1967 Feb 4;80(5):195-8. [Article]
  7. Lyons ET, Drudge JH, Tolliver SC: Haloxon: critical tests of antiparasitic activity in equids. Am J Vet Res. 1981 Jun;42(6):1043-5. [Article]
  8. Kingsbury PA, Rees TA, Piercy DW: Haloxon as an anthelmintic for dogs and cats. Vet Rec. 1977 Dec 10;101(24):477-9. [Article]
  9. Rose RJ, Hartley WJ, Baker W: Laryngeal paralysis in Arabian foals associated with oral haloxon administration. Equine Vet J. 1981 Jul;13(3):171-6. [Article]
  10. Baker NF, Douglas JR, Fisk RA: Anthelmintic activity of haloxon in calves with parasitic gastroenteritis. Am J Vet Res. 1969 Dec;30(12):2233-5. [Article]
ChemSpider
9082
ChEMBL
CHEMBL1897362
ZINC
ZINC000002040826
Wikipedia
Haloxon

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0206 mg/mLALOGPS
logP3.4ALOGPS
logP3.87Chemaxon
logS-4.3ALOGPS
pKa (Strongest Basic)-7.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area71.06 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity91.13 m3·mol-1Chemaxon
Polarizability37.1 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ik9-0007900000-8175239dd8c02d656b1c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0089-9350100000-7f4f75acc3665456bbe3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0090000000-7faa0e431917d8ee8432
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0089-9453000000-d15f510113040b346a00
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00ym-1297000000-39066ccda7caa4e070ce
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0089-9150000000-554dc6fc787eba42bf9b
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-176.06255
predicted
DeepCCS 1.0 (2019)
[M+H]+178.42097
predicted
DeepCCS 1.0 (2019)
[M+Na]+184.51411
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:37 / Updated at February 21, 2021 18:53